Navamedic ASA

Navamedic ASA maintains a capital structure characterized by zero debt, with a debt-to-equity ratio of 0.0. The balance sheet shows total assets of 512.3 million NOK against total liabilities of 335.1 million NOK, resulting in total equity of 177.2 million NOK. The company reported revenue of 52.8 million NOK in the latest period.

Profitability metrics indicate significant losses, with a return on equity of -9.14% and a return on assets of -3.16%. The company recorded an operating income of -17.8 million NOK and a net income of -16.7 million NOK. These negative returns reflect the current stage of the business, where operational costs exceed revenue generation.

Segment and geographic revenue breakdowns are not available in the provided data. Consequently, specific revenue concentration risks by segment or region cannot be quantified. The analysis relies on aggregate financial figures for the entire entity.

Historical growth trajectory data, including five-year annual and eight-quarter quarterly trends, is absent from the input. Therefore, no assessment of revenue momentum or net income trends over time can be made. The current snapshot provides a static view of financial performance without historical context.

Risk assessment indicates that liquidity and dilution risks are unknown. Key flags note that risk could not be fully assessed due to limited financial snapshot details and source documents. The absence of specific risk metrics prevents a detailed evaluation of financial stability or potential share dilution pressures.

Recent observations include analyst estimates with a mean price target of 23.50 NOK and a median target of 23.50 NOK, suggesting a potential upside from the current market price of 18.75 NOK. The mean recommendation is 2.00, with two buy ratings and no hold or strong buy ratings. Additionally, a management event was recorded involving the addition of a board member, indicating changes in corporate governance.

Navamedic ASA (NAVA) has undergone a complete leadership overhaul, with the addition of a new CEO and two new Board members alongside the departure of the former CEO and two outgoing Board members. This significant management event, detected on July 16, 2026, represents a notable shift in the company's governance structure, marking a fresh start for the organization's executive and oversight teams. The restructuring involves the appointment of a new Chief Executive Officer to lead the company's operations, supported by the integration of two new individuals into the Board of Directors. Concurrently, the previous CEO and two existing Board members have stepped down from their roles, indicating a deliberate transition in strategic direction and corporate stewardship. This change is particularly material given Navamedic's current profile, which includes a single officer and no analyst coverage, index membership, or identified top holders. The absence of prior financial analysis or market tracking for the ticker means this leadership reset establishes the foundational management team for future corporate developments and potential market engagement. As this is the first analysis for Navamedic ASA, there is no prior basis for computing deltas in performance or sentiment. The significance of these management changes lies in their role as the initial benchmark for the company's governance, setting the stage for future operational execution and strategic decision-making under the new leadership.

Revenue grew at a 19.4% CAGR over four years, demonstrating strong top-line expansion momentum.

Analysts project 38.7% upside to a consensus price target of 26.0 NOK, signaling bullish sentiment.

Gross profit increased to 220.3 million NOK in FY2026, indicating improving core profitability before operating expenses.

Free cash flow turned positive at 5.4 million NOK in FY2026, recovering from a negative position in FY2024.

Capex intensity is above the 75th percentile of peers, suggesting significant investment in future growth drivers.

Debt-to-equity ratio stands at 1.89, classified as high leverage, increasing financial risk and interest burden.

Return on equity is -9.14%, placing the company in the bottom quartile of its pharmaceutical peer cohort.

Operating margin of 0.82% remains significantly below the 5.6% median for the pharmaceutical sector.

Current ratio of 0.46 indicates potential liquidity constraints, as current assets cover less than half of current liabilities.

Revenue kr 137.9M, +4,5% YoY; Operating income −80,1% YoY.

• ▍Revenue kr 137.9M, +4,5% YoY
• ▍Operating income −80,1% YoY
• ▍Net income +98,4% YoY
• ▍Free cash flow +333,3% YoY
• ▍Net margin -0.1%

Revenue kr 157.1M, +19,8% YoY; Operating income +58,1% YoY.

• ▍Revenue kr 157.1M, +19,8% YoY
• ▍Operating income +58,1% YoY
• ▍Net income +59,0% YoY
• ▍Free cash flow +115,2% YoY
• ▍Net margin -7.0%

Revenue kr 138.9M, +12,9% YoY; Operating income −103,9% YoY.

• ▍Revenue kr 138.9M, +12,9% YoY
• ▍Operating income −103,9% YoY
• ▍Net income −391,8% YoY
• ▍Free cash flow +13,5% YoY
• ▍Net margin -2.5%

Revenue kr 137.3M, −12,2% YoY; Operating income −79,4% YoY.

• ▍Revenue kr 137.3M, −12,2% YoY
• ▍Operating income −79,4% YoY
• ▍Net income −107,9% YoY
• ▍Free cash flow −90,1% YoY
• ▍Net margin -1.1%

Revenue kr 132.0M; Operating income kr 9.2M.

• ▍Revenue kr 132.0M
• ▍Operating income kr 9.2M
• ▍Net margin -5.6%

Revenue kr 131.2M; Operating income -kr 6.8M.

• ▍Revenue kr 131.2M
• ▍Operating income -kr 6.8M
• ▍Net margin -20.5%

Revenue kr 123.1M; Operating income kr 4.8M.

• ▍Revenue kr 123.1M
• ▍Operating income kr 4.8M
• ▍Net margin 1.0%

Revenue kr 156.3M; Operating income kr 28.5M.

• ▍Revenue kr 156.3M
• ▍Operating income kr 28.5M
• ▍Net margin 12.5%

Revenue kr 565.4M, +6,4% YoY; Operating income −14,3% YoY.

• ▍Revenue kr 565.4M, +6,4% YoY
• ▍Operating income −14,3% YoY
• ▍Net income −329,1% YoY
• ▍Free cash flow −8,6% YoY
• ▍Net margin -4.2%

Revenue kr 531.4M, +3,8% YoY; Operating income +222,9% YoY.

• ▍Revenue kr 531.4M, +3,8% YoY
• ▍Operating income +222,9% YoY
• ▍Net income +59,9% YoY
• ▍Free cash flow +250,2% YoY
• ▍Net margin -1.0%

Revenue kr 512.0M, +34,0% YoY; Operating income −88,5% YoY.

• ▍Revenue kr 512.0M, +34,0% YoY
• ▍Operating income −88,5% YoY
• ▍Net income −146,5% YoY
• ▍Free cash flow −111,5% YoY
• ▍Net margin -2.7%

Revenue kr 382.1M, +37,2% YoY; Operating income +371,0% YoY.

• ▍Revenue kr 382.1M, +37,2% YoY
• ▍Operating income +371,0% YoY
• ▍Net income +4 662,5% YoY
• ▍Free cash flow +421,1% YoY
• ▍Net margin 7.7%